1/47
Looks like no tags are added yet.
What is the foundation and pillars of diabetes management?
Foundation → lifestyle modification and diabetes education
Pillars → Glycemic, BP, and lipid management and agents with cardiovascular/kidney benefit
Macrovascular complications of diabetes?
ASCVD → myocardial infraction (MI), cerebrovascular accident (CVA), Peripheral artery disease (PAD)
Heart failure
Microvascular complications of diabetes?
Nephropathy/CKD
Neuropathy
Retinopathy
When to screen for A1c with diabetes?
Every 3-6 months
When to screen for UACR with diabetes?
Yearly
When to screen for dilated eye exam with diabetes?
Yearly to every 2 years depending on risk
When to screen for lipid panel with diabetes?
Yearly
When to screen for creatinine with diabetes?
Yearly or more frequent depending on medication use → metformin/SGLT2i
Physical assessment screening for diabetes?
Blood pressure → regularly
Foot exam → Yearly
When to start screenings for T1D?
Can wait 5 years after diagnosis for regular screens → unless other risk factors
When to start screenings for T2D?
Start screenings right away
Why are personalized A1c goals important?
To balance glucose control with the risk of hypoglycemia and other side effects
At what A1c level does the risk of complications consistently increase?
A1c > 8.0% consistently
Goal blood pressure in diabetes?
<130/80 mmHg
What if BP of above >150/90 in diabetes?
Start 2 preferred agents:
ACE/ARB
CCB → amlodipine/nifedipine
Thiazide diuretic → chlorthalidone/indapamide preferred
What is diabetes considered in ASCVD risk assessment?
Diabetes is an ASCVD risk-enhancing factor
Lipid management primary prevention in patients with DM age 40-75?
Moderate intensity statin
LDL goal for primary prevention in patients with DM age 40-75 with PREVENT-ASCVD < 10%?
Goal LDL < 100
LDL goal for primary prevention in patients with DM age 40-75 with PREVENT-ASCVD ≥ 10%?
Goal LDL < 70
Typically means multiple ASCVD risk factors
Lipid management secondary prevention in patients with DM?
High intensity statin
Consider a 50% LDL lowering and/or LDL <50
Moderate intensity statin therapy?
Lowers LDL → 30-49%
Atorvastatin 10-20 mg
Rosuvastatin 5-10 mg
Simvastatin 20-40 mg
Pravastatin 40-80 mg
Lovastatin 40-80 mg
Fluvastatin XL 80 mg
Pitavastatin 1-4 mg
High intensity statin therapies?
Atorvastatin 40-80 mg
Rosuvastatin 20-40 mg
What if unable to reach LDL goals?
2nd therapies include →
Ezetimibe
PCSK9 inhibitors
Bempedoic acid is recommended IF they are statin intolerant
What if they have ASCVD or high risk indicators?
Use →
SGLTi
GLP-1 receptor agonists → Semaglutide/Dulaglutide
GIP/GLP combo agonist → Tirzepatide
Pioglitazone → LAST LINE, avoid in HF
What if they have heart failure?
Prioritize SGLT2 inhibitors
Then → Semaglutide, Tirzepatide, especially in HFpEF and obesity
What if they have CKD?
On max tolerated dose of ACE/ARB
Then use → SGLT2i most favorable
Especially with common complications in diabetes
Albuminuria/Proteinuria
UACR of >30mg/g
Even if eGFR is >60ml/min
When do you consider finerenone in CKD?
Simultaneous initiation of an SGLT2 inhibitor and a nonsteroidal MRA (finerenone) can be considered in adults with type 2 diabetes already on max tolerated RAAS inhibition therapy if →
AND: UACr ≥100 mg/g
AND: eGFR 30–90 mL/min/1.73 m2
Make sure Potassium is not super elevated before initiation (ideal < 4.8 mEq/L, monitor closely if 4.9-5.0 mEq/L
First line neuropathic pain treatment options?
Pregabalin / Gabapentin
SNRIs → duloxetine, venlafaxine
TCAs → amitriptyline
Sodium channel blockers → lamotrigine, lacosamide, carbamazepine, oxcarbazepine, valproic acid
Addition options for neuropathic pain treatment?
Capsaicin
Lidocaine patches
Alpha-lipoic acid
What to keep in mind with neuropathic pain treatment options?
The agents provides symptomatic improvement but do not prevent/reverse progression
Better blood glucose may slow progression but cannot reverse neuronal loss
When is aspirin considered for primary prevention in patients with diabetes?
Typically not recommended; individual risk/benefit discussion
May consider ages 50–69 with at least one additional ASCVD risk factor and no increased bleeding risk
What additional risk factors support considering aspirin for primary prevention?
Family history of premature ASCVD
Hypertension
Dyslipidemia
Smoking
CKD/albuminuria
When is aspirin recommended for secondary prevention?
Recommended → aspirin 81 mg daily
What causes diabetic neuropathy?
Increased blood glucose leads to insulin resistance, dyslipidemia, and oxidative stress
These cause inflammation and cellular damage to nerve fibers
Symptoms of peripheral neuropathy?
Burning
Sharp pain
Cold sensation
Numbness
Up to 50% may be asymptomatic
Symptoms of autonomic neuropathy?
Orthostatic hypotension, dizziness
Resting tachycardia
Dry or cracked skin in the extremities
Gastroparesis, constipation, diarrhea
Erectile dysfunction
Neuropathy screening?
At least annually
Peripheral neuropathy → foot exam
Autonomic neuropathy → monitor for symptoms
Foot exam dermatologic inspection?
Skin status
Sweating
Infection
Ulceration
Calluses/blistering
Foot exam musculoskeletal inspection?
Deformities
Muscle wasting
Foot exam neurological assessment?
10-g monofilament plus 1 of the following →
• Vibration using 128-Hz tuning fork
• Pinprick sensation
• Ankle reflexes
• Vibration perception threshold (VPT)
Foot exam vascular assessment?
Foot pulses
Ankle brachial index → if indicated
Retinopathy?
Hyperglycemia and/or uncontrolled blood pressure damage the blood vessels supplying the retina
Retinopathy screening and treatment?
Screening → Annually with dilated eye exam, can be spread out every 2 years
Treatment → No specific pharmacotherapy recommended to treat / prevent progression, just controlling glucose concentrations and BP
What eye complication has been associated with SQ semaglutide (Ozempic)?
Increased incidence of diabetic retinopathy complications
What is NAION?
Non-arteritic anterior ischemic optic neuropathy
11/26 → warning added to all GLP-1 products
What is the proposed mechanism behind GLP-1-related eye complications?
Rapid improvement in hyperglycemia → especially in patients with uncontrolled diabetes
What are the risk factors for diabetic retinopathy complications with GLP-1 therapy?
Pre-existing diabetic retinopathy
Large (>1.5%) and rapid (≤16 weeks) A1c reduction
Which vaccines are recommended for adults with diabetes?
Hepatitis B → ages 19–59
Pneumococcal → PCV20 or PCV21
RSV → consider for adults >60 due to increased risk
And Tdap, Shingles, influenza, covid-19 per normal adult schedule